idiopathic%20pulmonary%20fibrosis
IDIOPATHIC PULMONARY FIBROSIS

Idiopathic pulmonary fibrosis is the progressive parenchymal scarring & loss of pulmonary function due to unidentifiable cause of lung injury.

It is a specific form of chronic fibrosing interstitial pneumonia with the histopathologic characteristics of usual interstitial pneumonia.

Approximately 5% of patients are asymptomatic. Common signs and symptoms are exertional dyspnea, nonproductive cough, finger clubbing and bilateral inspiratory crackles.

Surgical Intervention

 Lung Transplantation

  • May be considered in idiopathic pulmonary fibrosis patients with moderate to severe disease
  •  Since idiopathic pulmonary fibrosis is a potentially rapid & progressive disease, the evaluation & opportunity for a transplantation is limited & is much shorter for patients with  idiopathic pulmonary fibrosis
    • Decision to undergo lung transplantation should be made within 3-6 months after initial diagnosis
    • Expected median survival is 34 months & applies after initial diagnosis of idiopathic pulmonary fibrosis
    • Once diagnosed, the patient must be referred immediately to a transplant center for evaluation
  •  A completion of at least 3 months of rehabilitation program is required before the patient may be considered for its eligibility for a transplantation
  • Patients who are 75 years old are still accepted in the transplant program
Acute Exacerbation of Idiopathic Pulmonary Fibrosis
  • Patients with acute exacerbation of idiopathic pulmonary fibrosis do not benefit from lung transplantation as perioperative risks are greater
    • ICU patients or those who are hooked to a mechanical ventilator may be at risk if subjected to a transplantation
Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS Respirology - Malaysia digital copy today!
Sign In To Download
Editor's Recommendations
Most Read Articles
Roshini Claire Anthony, 11 Sep 2019

Beta-blockers could reduce mortality risk in patients with heart failure with reduced ejection fraction (HFrEF) and moderate or moderately-severe renal dysfunction without causing harm, according to the BB-META-HF* trial presented at ESC 2019.

Elvira Manzano, 2 days ago

The US Preventive Services Task Force (USPSTF), in an update of its 2013 recommendations, called on clinicians to offer risk-reducing medications to women who are at increased risk for breast cancer but at low risk for adverse effects.

Pearl Toh, 3 days ago
The use of SGLT-2* inhibitors was not associated with a higher risk of severe or nonsevere urinary tract infections (UTIs) in patients with type 2 diabetes (T2D) compared with DPP**-4 inhibitors or GLP-1*** receptor agonists, a population-based cohort study shows.
6 days ago
In type 2 diabetes patients taking sulfonylureas, hypoglycaemia duration is longer at night and is inversely correlated with the level of glycated haemoglobin (HbA1c), a new study reports.